AC Immune boosts its preclinical Alzheimer´s pipeline
Prof. Andrea Pfeifer, CEO of AC Immune, said: “The in-licensing of the memory enhancer ACI-518 complements our product pipeline as it provides another route to develop a therapeutic for Alzheimer´s disease. We are delighted to build on the excellent track record of the University of Moscow in the field of AMPAkines. It is also pleasing to note that our first proprietary Morphomer ACI-636 for Alzheimer´s disease has entered preclinical development.”
AMPAkines are positive modulators of AMPA receptors, the non-NMDA ionotropic receptors for glutamate involved in long-term potentiation processes and short-term memory in humans. ACI-518 is a patent-protected lead molecule of the class of AMPAkines developed from the State University of Moscow, the institute which generated Dimebon currently under Phase III clinical development for Alzheimer’s disease by Medivation/Pfizer. ACI-518 shows the highest reported receptor affinity and is a very innovative approach to enhance the AMPA receptor function. AC Immune has acquired an exclusive license from the State University of Moscow and will use its proven expertise in preclinical development of Alzheimer´s treatments to move the compound forward quickly towards clinical development. No financial terms were disclosed.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.